Cg Oncology, Inc. · NASDAQ:CGON
Cg Oncology — ASCO Annual Meeting 2025
9 slides from Cg Oncology's conference presentation, Jun 2, 2025
Slide 1: Updates to CORE-008: Phase 2 Study of Cretostimogene in High-Risk NMIBC
TPS4625 Updates to CORE-008: A Phase 2 Multi-Arm, Multi-Cohort Study to Evaluate Intravesical Cretostimogene Grenadenorepvec in Patients with High-Risk Non-Muscle Invasive Bladder Cancer Gary D. Steinberg, MD,1* Trinity J. Bivalacqua, MD, PhD,2 Siamak Daneshmand, MD,3 Neal D. Shore, MD,4 Shreyas S.
Slide 2: Updates to CORE-008: A Phase 2 Multi-Arm, Multi-Cohort Study
Updates to CORE-008: A Phase 2 Multi-Arm, Multi-Cohort Study to Evaluate Intravesical Cretostimogene Grenadenorepvec in Patients with High-Risk Non-Muscle Invasive Bladder Cancer Copies of this poster obtained through Quick Response (QR) Gary D. Steinberg, MD Code are for personal use only and may n
Slide 3: Oncolytic Immunotherapy: Cretostimogene Grenadenorepvec's Dual Mechanism of Action
Oncolytic Immunotherapy: Chain Reaction of Cancer Cell Death: Cretostimogene Grenadenorepvec's Dual Viral progeny spread to additional Mechanism of Action tumor cells ») Selectively Replicates in and / Lyses Bladder Cancer Cells (2 \ Simultaneously Amplifies Innate to Adaptive Immune Switch: \&/ Ant
Slide 4: Considerable Unmet Needs in High-Risk NMIBC
Considerable Unmet Needs in High-Risk NMIBC • Guidelines currently recommend IVE BCG or radical cystectomy • Challenges with BCG o Despite high initial response rates, over 50% of patients will recur1 o 20-40% are at risk for progression2,3 o Ongoing BCG shortages4 • Risks with radical cystectomy o
Slide 5: Broad High-Risk NMIBC Study Population
Broad High-Risk* NMIBC Study Population * High-Risk NMIBC eligibility per AUA/SUO guideline criteria 4 Roumiguié M, Kamat AM, Bivalacqua TJ, et al. Eur Urol. 2022 Jul;82(1):34-46. doi: 10.1016/j.eururo.2021.12.005. Epub 2021 Dec 23.
Slide 6: Phase 2, Multi-Cohort, Open-Label Study of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Phase 2, Multi-Cohort, Open-Label Study of Cretostimogene Grenadenorepvec in High-Risk NMIBC Key Secondary Endpoints Duration of Response All-Cause Event Free Survival Bladder Cancer Specific Survival Cystectomy-Free Survival Safety Tolerability CORE-008 will investigate cretostimogene as monotherap
Slide 7: Cohort CX: Possible Synergism Between Cretostimogene & Gemcitabine
Cohort CX: Possible Synergism Between Cretostimogene & Gemcitabine Cretostimogene • Efficacy, safety, and tolerability Gemcitabine demonstrated as monotherapy and in combination • Pre-clinical synergy with gem and Oncolysis oncolytic immunotherapy in other tumor ✓ Release of cytokine/antigen types ✓
Slide 8: Treatment & Assessment Schedule
Treatment & Assessment Schedule Legend IVE creto IVE gem • Cystoscopy & Cytology every 3 months • CT/MRU every 6 months • Re-induction allowed for patients with HG Ta and/or CIS at Month 3 • Treatment is optional in Year 3 7
Slide 9: CORE-008 is Actively Enrolling
CORE-008 is Actively Enrolling • Cohort A (BCG-Naïve) o CIS containing arms have completed enrollment - First Results 2H2025 o HG Ta/T1 arm planned • Cohort B (BCG-Exposed) o Planned and received collaborative SUO-CTC support • Cohort CX (BCG-Exposed & BCG-UR) o First patients randomized 8